Provided by Tiger Trade Technology Pte. Ltd.

Pfizer

27.65
+0.55002.03%
Post-market: 27.53-0.1200-0.43%19:59 EST
Volume:41.88M
Turnover:1.15B
Market Cap:157.21B
PE:20.33
High:27.67
Open:27.16
Low:27.09
Close:27.10
52wk High:27.94
52wk Low:20.92
Shares:5.69B
Float Shares:5.68B
Volume Ratio:1.18
T/O Rate:0.74%
Dividend:1.72
Dividend Rate:6.22%
EPS(TTM):1.36
EPS(LYR):1.36
ROE:8.58%
ROA:5.19%
PB:1.69
PE(LYR):20.27

Loading ...

Rothschild & Co Redburn Adjusts Price Target on Pfizer to $25 From $23, Maintains Neutral Rating

MT Newswires Live
·
Feb 17

Pfizer Targets Real‑World Proof for Ritlecitinib in Severe Alopecia Areata

TIPRANKS
·
Feb 14

Pfizer Advances VESPER-5 Obesity and Diabetes Trial, Targeting a Key Growth Market

TIPRANKS
·
Feb 14

Mixed options sentiment in Pfizer with shares down 0.38%

TIPRANKS
·
Feb 13

Daiwa Securities Downgrades Pfizer to Neutral From Outperform, Price Target is $27

MT Newswires Live
·
Feb 12

Pfizer downgraded to Neutral from Outperform at Daiwa

TIPRANKS
·
Feb 12

Protalix BioTherapeutics Showcases Pipeline Advancements and Innovations in Rare Disease Therapies

Reuters
·
Feb 12

Pfizer Balances New Therapies And Pricing With Fresh Biotech Partnerships

Simply Wall St.
·
Feb 12

Pfizer to collect $29 million from SEC case against Steven A. Cohen hedge fund

Reuters
·
Feb 11

Pfizer Inc. Publishes Transcript of Q4 2025 Earnings Call Event

Reuters
·
Feb 11

Pfizer Dec-Quarter Net Profit 1.42 Billion Rupees

Reuters
·
Feb 09

DIARY-India economic, corporate events on February 9

Reuters
·
Feb 09

TrumpRx Is Here. Most People Won't Benefit. -- Barrons.com

Dow Jones
·
Feb 07

Pfizer Halts Early-Stage Trial for PF-07258669 in Older Adults: What Investors Should Know

TIPRANKS
·
Feb 07

Pfizer Completes Mid-Stage Trial of New Obesity Drug Candidate PF-07976016

TIPRANKS
·
Feb 07

Pfizer says FDA grants Priority Review for sBLA for Hympavzi

TIPRANKS
·
Feb 06

FDA prüft Zulassung von HYMPAVZI für Patienten mit Hämophilie und Inhibitoren

Reuters
·
Feb 06

FDA Grants Priority Review for Hympavzi® (Marstacimab) Sbla for the Treatment of Two Hemophilia a or B Patient Populations With Significant Medical Need

THOMSON REUTERS
·
Feb 06

Pfizer - FDA Sets Pdufa Action Date for Hympavzi in Q2 2026

THOMSON REUTERS
·
Feb 06

White House Debuts Drug-Buying Site TrumpRx, With Roughly 40 Medications -- WSJ

Dow Jones
·
Feb 06